Q-linea (QLINEA) Q2 2024 earnings summary

Executive summary

• Achieved FDA approval for ASTar platform in April 2024, enabling full US commercial launch and global expansion, with initial focus on top US labs and first instruments shipped.

• Cost-saving program completed, expected to generate SEK 50 million in annual run-rate savings from Q3 2024.

• Extended SEK 101.5 million loan facility from main shareholder Nexttobe, with SEK 60 million unutilized as of June 30, providing runway into the latter part of the year.

• Geographic expansion continues with new sales in Italy and participation in Belgian tenders; distribution partners sought across EMEA/ROW.

• CMS recommended NTAP reimbursement of $97.50 per Medicare patient for ASTar, pending final approval.

Financial highlights

• Q2 2024 operating result was SEK -57 million excluding SEK 8.4 million in restructuring costs; Q2 net sales were SEK 0.2 million, down from SEK 1.4 million year-over-year.

• Earnings per share for Q2 2024 was SEK -0.56, compared to -2.23 in Q2 2023.

• Cash and available loan facility totaled SEK 80.9 million as of June 30, with SEK 20.9 million in cash and SEK 60 million in unused loan facility.

• Average monthly burn rate in Q2 was SEK 16.7 million, slightly lower than H1 average.

• Q2 cash flow from operating activities improved to SEK -44.1 million (Q2 2023: -53.5 million).

Outlook and guidance

• Full effect of SEK 50 million annual cost savings expected in Q3 and Q4 2024.

• Confident in ability to finance operations, but current liquidity and loan facilities are insufficient for the next 12 months without further funding; alternative financing options are being pursued.

• US commercialization and reagent rental model expected to drive growth, though revenue recognition is delayed.